These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 31781306)
1. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node Involvement. Bonin S; Pracella D; Barbazza R; Dotti I; Boffo S; Stanta G Dis Markers; 2019; 2019():7832376. PubMed ID: 31781306 [TBL] [Abstract][Full Text] [Related]
2. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis. Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107 [TBL] [Abstract][Full Text] [Related]
3. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer. Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033 [TBL] [Abstract][Full Text] [Related]
4. Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer. Inoue T; Nishi T; Nakano Y; Nishimae A; Sawai Y; Yamasaki M; Inaji H Breast Cancer; 2016 Mar; 23(2):295-300. PubMed ID: 25348937 [TBL] [Abstract][Full Text] [Related]
5. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487 [TBL] [Abstract][Full Text] [Related]
6. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era? Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439 [TBL] [Abstract][Full Text] [Related]
7. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients. Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847 [TBL] [Abstract][Full Text] [Related]
8. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival. Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770 [TBL] [Abstract][Full Text] [Related]
9. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer. Li Y; Qin J; Wu J; Dai X; Xu J Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822 [TBL] [Abstract][Full Text] [Related]
11. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747 [TBL] [Abstract][Full Text] [Related]
12. Ki-67 is a prognostic marker for hormone receptor positive tumors. ; ; . PubMed ID: 26742937 [TBL] [Abstract][Full Text] [Related]